News and Announcements
Inside Healthcare Investing: How KP Rx is Transforming Australia’s Biotech Industry
- Published November 08, 2024 5:04AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Join us in this in-depth interview with Hashan De Silva, Founder of KP Rx, as he shares the journey behind launching a specialist healthcare VC firm. Learn how KP Rx is transforming biotech and medical device investments in Australia and New Zealand by capitalising on key market advantages. Hashan explains the firm’s unique approach, valuation arbitrage, and insights into healthcare investment strategies that have yielded significant success.
Executive Interviews
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
